Thomson Reuters Corp (TRI.TO) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Thomson Reuters Corp (TRI.TO)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

114.51

-0.36 (0.31%)

as of Jun 10, 2026, 8:00:00 pm Market Open.

214 watching

Investor Insights

Jun 9, 2026, 12:00 am

This summary was created by AI, based on 32 opinions in the last 12 months.

Thomson Reuters Corp (TRI-T) continues to evoke mixed opinions from experts, with many emphasizing its valuable proprietary data, especially for legal and accounting sectors. Some analysts recognize its potential to leverage AI technologies to enhance efficiency and product offerings. However, concerns around valuation persist, particularly with the stock's historical high PE ratios and recent downward trends. While there are varying perspectives on how AI may disrupt its core business, some analysts see TRI's unique data moat as a strong competitive advantage that may help it maintain resilience. Overall, while there are advocates for its long-term potential, there are also cautionary notes regarding its current market assessment and future revenue impacts from technological advancements.

Consensus

Hold

Valuation

Fair Value

Similar

Bloomberg, BDN

COMMENT

Has been a busy year with selling off some assets and acquiring others. Tends to trade at a fairly rich price/earnings ratio, so your entry points have to be critical.

TOP PICK

Believes the market is underestimating what they combination with Reuters is going to do for them. Have been very good at making data available to the legal world but also giving analytical tools for research. Reuters has lacked this.

DON'T BUY

Media companies have been having a tough time. Pullback in price is not company specific, but is due to a weak market/sector. Has had a hard time rallying in the last bull market, so will have a tougher time in a weak market.

TOP PICK

Likes the merger with Reuters. This is causing a big stir in Europe because Reuters is heavily European. Think they will do well.

BUY

This is about legal, medical and other specialized information. Recently acquired Reuters. Should do pretty well.

TOP PICK

The Reuters acquisition is a company-changing event. It’ll put the company into 1st place in terms of financial services. Gives it a global footprint. Likes the long-term potential of financial services. Good price.

BUY

This one may be a little bit economy/interest sensitive. It is right back down to support again. Thanks it is okay.

TOP PICK

Most of their business is in the US so have had currency headwinds. Have great databases. Stock has come off because of the Reuters acquisition. Feels this transaction is going to add further value to the stock.

PAST TOP PICK

(A Top Pick Feb 27/07. Down 6.1%.) The recent Reuters acquisition can be a very positive and accretive one for them.

DON'T BUY

As being extremely volatile over the last few months. Their acquisition of Reuters is an excellent long-term strategic move. In the near term, it is expensive. There could be a share issue, which might be an opportunity to Buy. Could also buy near the last low of about $41.

TOP PICK

Very optimistic on their Reuters acquisition. At this price, a good long-term Buy. The cash flow generating capability is going to be tremendous going forward.

WEAK BUY

A great company, one of the best in it's field. But is expensive at 23 to 25 times earnings. If you are a trader, you can buy at around 40 and sell at 50, and make some money, but otherwise buy for the long term (2 to 3 years).

BUY

The Reuters acquisition was a terrific play for them. This will really elevate their opportunities globally for higher margins.

DON'T BUY

Acquisition of Reuters puts them head-to-head with Bloomberg's has investors nervous. Investors have been under rewarded with this company in the past.

PAST TOP PICK

Then $44.78 In a business that they really like. They cater to the professional market.

Showing 421 to 435 of 710 entries

Most Recent Experts

Kim Bolton

Black Swan Dexteritas

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Baskin Wealth Management

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Thomson Reuters Corp (TRI.TO)